Step 1 topics → Reproductive → Prostate Adenocarcinoma

Prostate Adenocarcinoma

USMLE Step 1 trap: Misidentifies prostate cancer bone metastases as osteolytic rather than osteoblastic. Prostate cancer characteristically produces osteoblastic (sclerotic) bone metastases, which appear as dense lesions on X-ray and cause elevated alkaline phosphatase.

Prostate adenocarcinoma is one of the highest-yield reproductive pathology topics on USMLE Step 1. It arises predominantly from the peripheral zone (posterior gland, palpable on DRE) — contrast this with BPH, which compresses from the transitional zone. The exam tests this topic across three main angles: the pathology of the tumor itself (zone, grading), its characteristic metastatic behavior, and hormonal management of advanced disease. You need to know all three.

What makes this topic tricky is the cluster of well-disguised misconceptions. Students frequently confuse PSA elevation with cancer diagnosis, misremember Gleason scoring as based on one pattern instead of two, and default to osteolytic mets because that's what most cancers cause. USMLE Step 1 loves to exploit these defaults — a vignette will describe dense lesions on X-ray with elevated alkaline phosphatase, and the wrong answer choice will be metastatic lung cancer (osteolytic). Knowing that prostate cancer is the classic osteoblastic exception is what separates a correct answer from a trap.

The hormonal therapy angle also catches people off guard. GnRH agonists are a standard treatment for advanced prostate cancer, but the mechanism has a counterintuitive first step: testosterone initially spikes (the 'flare') before receptor downregulation kicks in. USMLE Step 1 can test this through a clinical scenario where a patient with metastatic prostate cancer worsens acutely after starting leuprolide — and you need to know why and how to prevent it.

From real student decks
62%have cards covering this topic
49%have mature cards

Common misconceptions

Common mistake
Wrong: Prostate cancer bone metastases are osteolytic like most other cancers.
Right: Prostate cancer characteristically produces osteoblastic (sclerotic) bone metastases, which appear as dense lesions on X-ray and cause elevated alkaline phosphatase.
Most cancers that metastasize to bone cause osteolytic lesions (bone destruction, hypercalcemia, radiolucent on X-ray) — lung, breast, renal, thyroid, and multiple myeloma are the classic culprits. Prostate cancer is the key exception: it drives osteoblastic activity, producing dense sclerotic lesions visible on plain X-ray and elevating alkaline phosphatase from increased osteoblast activity. When a vignette shows an older man with back pain, dense vertebral lesions, elevated ALP, and elevated PSA, that's the classic prostate metastasis picture — don't default to osteolytic just because bone mets are involved.
Common mistake
Wrong: An elevated PSA is specific for prostate cancer.
Right: PSA is organ-specific but not cancer-specific; it is also elevated in BPH, prostatitis, and after prostate manipulation.
PSA (prostate-specific antigen) is produced by prostate epithelium — it's organ-specific, not cancer-specific. BPH, prostatitis, and even mechanical manipulation of the prostate (DRE, biopsy, cystoscopy) all raise PSA levels. This means an elevated PSA flags something going on in the prostate, but it cannot diagnose cancer on its own. On Step 1, a question that asks what an elevated PSA 'indicates' requires you to pick the most appropriate interpretation — which is always further evaluation, not a cancer diagnosis.
Common mistake
Wrong: The Gleason score is based on the single most common histologic pattern.
Right: The Gleason score is the sum of the two most prevalent architectural patterns (primary + secondary), each graded 1–5, for a total of 2–10.
The Gleason system grades tumor architecture (glandular differentiation), not cytology. Crucially, it accounts for tumor heterogeneity by scoring the two most prevalent patterns separately — the primary (most abundant) pattern and the secondary (second most abundant) pattern — each on a 1–5 scale. The final Gleason score is their sum, ranging from 2 to 10. A score based on just one pattern would miss the prognostic significance of heterogeneity. On the exam, if you see a question about Gleason grading, remember: two patterns, added together.
Common mistake
Wrong: GnRH agonists immediately suppress testosterone when started for prostate cancer.
Right: GnRH agonists initially cause a testosterone flare before downregulation; antiandrogens are co-administered at initiation to block this flare.
GnRH agonists like leuprolide work through receptor downregulation, but this takes time. In the first 1–2 weeks, continuous GnRH receptor stimulation actually increases LH and FSH secretion, causing a transient testosterone surge — the 'flare.' In a patient with metastatic prostate cancer, this flare can temporarily worsen bone pain or even trigger spinal cord compression. To prevent this, antiandrogens (e.g., flutamide, bicalutamide) are started before or simultaneously with the GnRH agonist to competitively block androgen receptors during that initial flare window.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know which zone of the prostate adenocarcinoma arises from (peripheral), how Gleason scoring works as a sum of two architectural patterns (primary + secondary, each 1–5, total 2–10), and why PSA elevation is organ-specific but not cancer-specific.
  2. Recognize that prostate cancer produces osteoblastic (not osteolytic) bone metastases — appearing as dense/sclerotic lesions on X-ray — and know the associated lab finding of elevated alkaline phosphatase.
  3. Understand androgen deprivation strategies for advanced prostate cancer, including the mechanism of GnRH agonists, the initial testosterone flare on starting therapy, and why antiandrogens must be co-administered at initiation to block that flare.

Can you avoid these mistakes?

A 68-year-old man is found to have a hard nodule on DRE. Biopsy shows malignant glands with loss of architecture. The pathologist reports the two most prevalent patterns as grade 3 and grade 4. What is his Gleason score, and what does it mean prognostically?
A 72-year-old man with known prostate cancer presents with severe low back pain. X-ray shows multiple dense, sclerotic lesions in the lumbar vertebrae. Labs show elevated alkaline phosphatase and PSA. What type of bone metastasis is this, and how does it differ from the pattern seen in lung cancer metastases?
A patient with metastatic prostate cancer is started on leuprolide. Two weeks later, his bone pain is significantly worse. What is the physiologic explanation, and what medication should have been started at the same time to prevent this?
A 65-year-old man has a PSA of 8 ng/mL on routine screening. His primary care physician tells him he has prostate cancer. What is wrong with this interpretation, and what are three other causes of an elevated PSA?

Related topics

Benign Prostatic Hyperplasia (BPH) Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →